Tumor lysis syndrome (TLS) is a potentially life-threatening metabolic disorder characterized by an elevated uric acid level, elevated serum potassium and phosphorus levels, and a decreased calcium level. Most often seen 12 to 72 hours after administration of systemic chemotherapy for a hematologic malignancy, TLS occasionally may be present prior to the start of therapy. Hematologic malignanci...

Background: The risk of injury to the kidney can be significantly exacerbated by presence tumors and effects related treatments. Kidney associated with cancer is common in multiple myeloma, tumor lysis syndrome, hematopoietic stem cell therapy, chemotherapy. Cancer patients are at increased infection, sepsis, drug-related toxicity, other comorbidities, leading a acute (AKI). This study retrospe...

Patients at highest risk for tumor lysis syndrome (TLS) often are diagnosed with bulky, rapidly proliferating hematologic tumors, such as acute leukemia and nonHodgkin lymphoma (Kaplow & Hardin, 2007). Patients with solid tumors, such as mediastinal masses which are highly sensitive to chemotherapy, also may develop TLS, although it is more common in patients undergoing treatment for leukemia a...